PA21
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hemodialysis Patients With Hyperphosphatemia
Conditions
Hemodialysis Patients With Hyperphosphatemia
Trial Timeline
Mar 18, 2013 → Aug 4, 2014
NCT ID
NCT01833494About PA21
PA21 is a phase 3 stage product being developed by Kissei Pharmaceutical for Hemodialysis Patients With Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01833494. Target conditions include Hemodialysis Patients With Hyperphosphatemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01852682 | Phase 3 | Completed |
| NCT01850641 | Phase 3 | Completed |
| NCT01833494 | Phase 3 | Completed |
Competing Products
20 competing products in Hemodialysis Patients With Hyperphosphatemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| ASP7991 | Astellas Pharma | Phase 1 | 33 |
| roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 77 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| ASP1585 | Astellas Pharma | Phase 2 | 52 |
| Kiklin capsules | Astellas Pharma | Pre-clinical | 23 |
| Doravirine | Merck | Approved | 85 |
| BPS804 + Placebo | Novartis | Phase 2 | 52 |
| PA21 + Sevelamer hydrochloride | Kissei Pharmaceutical | Phase 3 | 76 |
| PA21 + PA21 + PA21 + PA21 + Placebo | Kissei Pharmaceutical | Phase 2 | 51 |
| PA21 | Kissei Pharmaceutical | Phase 3 | 76 |
| [¹⁴C]Etelcalcetide | Amgen | Phase 1 | 32 |
| Epoetin Hospira | Pfizer | Phase 3 | 76 |
| Epoetin Hospira | Pfizer | Phase 3 | 76 |
| sodium thiosulfate | Sanofi | Pre-clinical | 22 |
| Enoxaparine | Sanofi | Approved | 84 |
| Alirocumab 150 MG/ML [Praluent] | Regeneron Pharmaceuticals | Phase 3 | 76 |